Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities

This preclinical study was triaged for T5 - Precision Oncology/Genomic Medicine based on abstract review. It appears standard priority because it addresses a direct clinical or diagnostic question with moderate evidence maturity.

This preclinical study was triaged for T5 - Precision Oncology/Genomic Medicine based on abstract review. It appears standard priority because it addresses a direct clinical or diagnostic question with moderate evidence maturity.

What the study was

Study design

Preclinical study

Sample size

191

Maturity

Validated

Journal

Science advances

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.